Back to Trials
NCT06494904PHASE3Recruiting

Standard Versus High Dose ED-Initiated Buprenorphine Induction

Yale University

Start Date

12/6/2024

Completion Date

12/1/2028

Summary

This study is a multisite double-blind, double-dummy, randomized clinical trial enrolling ED patients with untreated moderate to severe opioid use disorder (OUD) to compare Standard Dose Induction (SDI) and High Dose Induction (HDI) on rates of participation in OUD treatment within 10 days post randomization, and opioid withdrawal symptoms, opioid craving, and use of illicit and non-prescribed drugs.

Detailed Description

This study will recruit, train, and provide resources to approximately 4 ED systems throughout the U.S. to recruit ED patients presenting with OUD not receiving medications for opioid use disorder (MOUD) as part of an RCT to compare SDI (Zubsolv 5.7/1.4 mg buprenorphine/naloxone\* plus 2 placebo tablets) with HDI (three Zubsolv 5.7/1.4 mg\* buprenorphine/naloxone tablets) to evaluate rate of participation in OUD treatment within 10 days post-randomization and differences in outcomes of tolerability, opioid withdrawal symptoms, craving, and use of illicit drugs.

Eligibility Criteria

Age Range: 18 years to 65 years

Inclusion Criteria: All patients enrolled into the study must: 1. Be 18-65 years of age. 2. Be treated in the ED during study screening hours. 3. Meet DSM-5 diagnostic criteria for moderate to severe OUD. 4. Have a Clinical Opiate Withdrawal Scale (COWS) score of ≥8 at enrollment (including 2 objective signs of withdrawal at enrollment). 5. Have a urine toxicology test that is positive for opioids. 6. Be able to speak English sufficiently to understand the study procedures and provide written informed consent to participate in the study. Exclusion Criteria: All patients enrolled into the study must not: 1. Have a medical or psychiatric condition that requires hospitalization at the time of index ED visit. 2. Have a known hypersensitivity reaction to buprenorphine/naloxone 3. Be actively suicidal or severely cognitively impaired precluding informed consent. 4. Require ongoing prescription for opioid analgesics. 5. Have a physical exam or reported history consistent with severe liver failure 6. Have a positive urine test for methadone and reported use in the past 72 hours 7. Be a prisoner or in police custody at the time of index ED visit. 8. Be unwilling to follow study procedures (e.g., unwilling to provide permission to contact referral provider/program or unavailable for the follow-up assessments) 9. Have prior enrollment in the current study. 10. Receiving MOUD treatment within the past 7 days. 11. Be pregnant as determined by human gonadotropin (hCG) testing at the index ED visit 12. Have a respiratory rate \<8 or oxygen saturation \<93% 13. Be a participant in any other clinical trial in which medications are being delivered or the use of an investigational drug or device within the last 30 days

Interventions

DRUG

Buprenorphine

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Opioid Use Disorder

Locations

Highland Hospital

Oakland, California 94602

United States

San Leandro Hospital

San Leandro, California 94578

United States

Maine Medical Center

Portland, Maine 04102

United States

Cooper University Hospital

Camden, New Jersey 08103

United States

University of Utah Hospital

Salt Lake City, Utah 84132

United States